

REDX PHARMA LIMITED

("Redx" or the "Company")

Redx scientist awarded the 2025 Malcolm J. Campbell Memorial Prize

The Royal Society of Chemistry's Biological and Medicinal Sector awarded Dr Nicolas E.S. Guisot, Ph.D., FRSC, Vice President, Head of Development Science at Redx the prize for pioneering the development of reversible BTK inhibitors

Alderley Park, UK, 21 March 2025 [Redx Pharma](#) (JPJ:REDX), the clinical-stage, small molecule biotechnology company's Head of Development Science, Dr Nicolas Guisot receives the award in recognition of successfully developing the first approved reversible Bruton's tyrosine kinase (BTK) inhibitor Pirtobrutinib (RXC005) for the treatment of adult patients with mantle cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.

The BTK inhibitor programme was subsequently sold to Loxo Oncology (now part of Eli Lilly) in July 2017. Eli Lilly brought Pirtobrutinib to market as Jaypirca™ in January 2023, following an FDA Accelerated Approval pathway.

Dr Nicolas E.S. Guisot, Ph.D., FRSC, Vice President, Head of Development Science at Redx: *"I am thrilled to accept the Malcolm J. Campbell Memorial Prize for 2025 on behalf of my colleagues at Redx. It is an honour to work with such talented scientists who are passionate and relentless in their pursuit to discover and develop best-in-class medicines in hard-to-treat diseases. I continue to be inspired everyday about what can be achieved via the practical application of chemistry".*

BTK was one of the first targets investigated at Redx for oncology when the company was formed. The initial aim of the BTK inhibitor programme was to develop a best-in-class irreversible inhibitor to overcome the shortfalls of ibrutinib, but our team quickly realised that targeting the emerging mutations observed

following treatment of ibrutinib would be key especially the C481S resistance mutation.

For the full announcement please visit

<https://www.rscbmcs.org/awards/malcolmcampbell/>

For further information, please contact:

T: +44 (0)1625 469 918

Redx Pharma Limited

Erin Hamid, Interim Head of
Communications

ir@redxpharma.com

FTI Consulting

T: +44 (0)203 727 1000

Simon Conway/ Ciara Martin

About Redx Pharma Limited

Redx Pharma (JPJ: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted therapeutics for the treatment of fibrotic disease. Redx aims to progress its programmes to clinical proof of concept before evaluating options for further development and potential value creation. The Company is currently progressing an industry leading ROCK inhibitor portfolio through the clinic, including zelasudil, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis and RXC008, a GI-restricted pan-ROCK inhibitor for the treatment of fibrostenotic Crohn's disease. Additionally, the Company has a Phase 2 precision oncology programme which it intends to partner for further development.

The Company has a strong track record of discovering new drug candidates through its core strengths in medicinal chemistry and translational science, enabling the Company to discover and develop differentiated therapeutics against biologically or clinically validated targets. To date, six Redx discovered molecules have been progressed into the clinic with the Company's accomplishments evidenced not only by its wholly-owned clinical-stage product candidates and discovery pipeline, but also by its strategic transactions, which includes the sale of pirtobrutinib (RXC005, LOXO-305), the only non-covalent or reversible BTK inhibitor now approved by the US FDA, and transactions with both AstraZeneca and Jazz Pharmaceuticals.